Mereo BioPharma (MREO) Change in Cash (2023 - 2026)

Mereo BioPharma (MREO) has reported Change in Cash for 4 consecutive years, with -$4.6 million the latest figure, recorded in Q1 2026.

• Quarterly Change in Cash rose 43.94% year-over-year to -$4.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$27.0 million (down 306.83% YoY) and the FY2025 annual result came in at -$30.7 million, down 343.09% from the prior year.
• Change in Cash climbed to -$4.6 million in Q1 2026 per MREO's latest filing, from -$7.6 million in the prior quarter.
• Over the last five years, Change in Cash for MREO reached as high as $38.9 million in Q2 2024 and fell as low as -$9.7 million in Q1 2023.
• A 4-year average of -$2.6 million and a median of -$7.7 million in 2023 frame the typical range for Change in Cash.
• The largest YoY upside for Change in Cash was 605.76% in 2024 against a maximum downside of 169.34% in 2024.
• Year by year, Change in Cash stood at -$5.1 million in 2023, then sank by 85.2% to -$9.5 million in 2024, then climbed by 19.21% to -$7.6 million in 2025, then soared by 39.66% to -$4.6 million in 2026.
• According to Business Quant data, Change in Cash over the past three periods registered -$4.6 million, -$7.6 million, and -$7.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.